Recruiting

Laser Treatment

Sponsor:

Cutera Inc.

Code:

NCT05430464

Conditions

Acne Vulgaris

Eligibility Criteria

Sex: All

Age: 16 - 50

Healthy Volunteers: Not accepted

Interventions

1726nm Laser System

Sham Laser System

Study Details

Brief summary:

The purpose of this study is to evaluate the onset, duration, efficacy and safety of the laser for the treatment of acne vulgaris.

Conditions

Acne Vulgaris

Study ID

NCT05430464

Start date

Jul 27, 2022

Status verified date

Sep, 2022

Completion date

Oct, 2024

Anticipated

Primary completion date

Apr, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 16 - 50

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Female or Male, 16 to 50 years of age (inclusive).
  • Fitzpatrick Skin Type I-VI
  • Has clinically diagnosed acne vulgaris of moderate to severe on each hemiface and inflammatory acne lesions as determined by the blinded trained investigator (or qualified designee) using the Investigator's Global Assessment Scale.
  • Subject (and legally authorized representative/substitute decision maker if subject is incapable of providing informed consent) must be able to read, speak, and understand English and sign the Informed Consent Form.
  • Willing to stop using topical acne medications on the face for 2 weeks prior to baseline and systemic acne medications for 1 month prior to baseline and for the duration of the study.
  • Willing and able to adhere to the treatment and follow-up schedule and pre/post-treatment care instructions.
  • Willing to have very limited sun exposure (including avoiding tanning booths, sun lamps, sunbathing) and use an approved sunblock or sunscreen of SPF (Skin Protection Factor) 30 or higher on the face every day for the duration of the study, including the follow-up period.
  • Willing to have photographs taken of the face and agree to the use of photographs for presentation, educational or marketing purposes.
  • Agree to not undergo any other procedure(s) or add any new treatment modalities in the target area during the study.

Exclusion Criteria:

  • Has clinically diagnosed acne vulgaris of severity grade of clear, almost clear, or mild on at least one hemiface as determined by the blinded trained investigator (or qualified designee) using the Investigator's Global Assessment Scale.
  • Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation.
  • Prior treatment to the target area within 1 month of study participation including chemical peel, dermabrasion/microdermabrasion, microneedling, radiofrequency treatment, laser or light-based procedures, cryodestruction or chemodestruction, intralesional steroids, photodynamic therapy, or acne surgery.
  • Prior injection of botulinum toxin in the target area within 1 month of study participation and for the duration of the study.
  • Prior injection of collagen, hyaluronic acid filler or other dermal/tissue filler in the target area within 2 weeks of study participation.
  • Systemic use of retinoid, such as isotretinoin, within 6 months of study participation.
  • Started or changed hormonal contraception within 6 months of study participation or intends to start or change hormonal contraception through duration of the study. If subject has not changed hormonal contraception within 6 months of study participation and has intent of continuation through duration of this study, ok to enroll.
  • History of malignant tumors in the target area.
  • Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) or facial adornments (studs, piercings, tattoos) that may preclude treatments, photos or accurate lesion assessments in the target area.
  • Pregnant and/or breastfeeding or planning to become pregnant during the study.
  • Presence of any skin condition in the target area (e.g., eczema, psoriasis, dermatitis, rash, papulo-pustular rosacea, infection) that would interfere with the diagnosis or assessment of acne vulgaris.
  • Any medical condition that, in the opinion of the Investigator, would interfere with patient's participation in the full study protocol (e.g., severe Diabetes Mellitus or Cardiovascular Disease).
  • Suffering from diagnosed coagulation disorders or taking prescription anticoagulation medications.
  • History of diagnosed immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
  • History of diagnosed connective tissue disease, such as systemic lupus erythematosus or scleroderma.
  • Known hypersensitivity to, history of allergic reaction to, or contraindication to Pro-Nox (or similar) if administered.
  • Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
  • History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the target area, unless treatment is conducted following a prophylactic regimen.
  • History of radiation to the target area, currently undergoing treatment for skin cancer in the target area or undergoing systemic chemotherapy for the treatment of cancer.
  • History of diagnosed pigmentary disorders (including vitiligo) in the target area.
  • Facial tan or unable/unlikely to refrain from tanning on the face during the study.
  • As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Study Design

Enrollment

30 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: 1726nm Laser Treatment

sham comparator: Sham Laser Treatment

Interventions

1726nm Laser System

Subjects will receive 1726nm laser treatments on one side of the face

Sham Laser System

Subjects will receive sham laser treatments on the other side of the face.

Primary outcome measure

  • Percent of subjects having at least a 1 point reduction on the Investigator Global Assessment Scale [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Spencer Royea

415-657-5531sroyea@cutera.com

Locations

Canadian Dermatology Centre

Recruiting

Toronto, Ontario, Canada, M3B 0A7

Contacts

Michelle Mooney

416-244-8377

Principal Investigator:

Renita Ahluwalia, MD

Windsor Clinical Research

Recruiting

Windsor, Ontario, Canada, N8W 5L7

Contacts

Shannon Moore

519-971-7693wcri@bellnet.ca

Principal Investigator:

Jerry Tan, MD

More Information

Sponsor

Cutera Inc.

Last update posted

Oct 4, 2022

Last verified

Sep, 2022

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Cutera Inc. on 2022-10-04.